Melanocortin Peptides: Potential Targets in Systemic Lupus Erythematosus

Inflammation

Volumn 38, Issue 1, 2015, Pages 260-271

  Loram, Lisa Carole ^a   Culp, Melissa Elizabeth ^a   Connolly Strong, Erin Corey ^a   Sturgill Koszycki, Sheila ^a  

^a MALLINCKRODT PHARMACEUTICALS   (United States)

Author keywords

adrenocorticotropin; immune; melanocortin; systemic lupus erythematosus

Indexed keywords

BLEOMYCIN; CORTICOTROPIN; GLUCOCORTICOID; LIPID; MELANOCORTIN; MELANOCORTIN 1 RECEPTOR AGONIST; MELANOCORTIN 2 RECEPTOR; MELANOCORTIN RECEPTOR; MELANOCORTIN RECEPTOR AGONIST; NITRIC OXIDE; PLACEBO; PREDNISOLONE; PROOPIOMELANOCORTIN; TETRACOSACTIDE; UNCLASSIFIED DRUG; PEPTIDE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; B LYMPHOCYTE; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG BIOAVAILABILITY; ENDOTHELIUM CELL; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY; KIDNEY INJURY; LIPID BLOOD LEVEL; LUPUS ERYTHEMATOSUS NEPHRITIS; MACROPHAGE; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHAGOCYTOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; RISK FACTOR; SKIN; SKIN MANIFESTATION; STEROIDOGENESIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; ANIMAL; DRUG DELIVERY SYSTEM; LUPUS ERYTHEMATOSUS, SYSTEMIC; METABOLISM; TRENDS;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MELANOCORTINS; PEPTIDES; RECEPTORS, MELANOCORTIN;

EID: 84922167074     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-014-0029-5     Document Type: Article

References (103)

1. Lo, M.S., and G.C. Tsokos. 2012. Treatment of systemic lupus erythematosus: New advances in targeted therapy. Annals of the New York Academy of Sciences 1247: 138–152.
2. Stohl, W., F. Hiepe, K.M. Latinis, M. Thomas, M.A. Scheinberg, A. Clarke, et al. 2012. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis and Rheumatism 64: 2328–2337.
3. Davis, L.S., J. Hutcheson, and C. Mohan. 2011. The role of cytokines in the pathogenesis and treatment of systemic lupus erythematosus. Journal of Interferon and Cytokine Research 31: 781–789.
4. Alunno, A., E. Bartoloni, O. Bistoni, G. Nocentini, S. Ronchetti, S. Caterbi, et al. 2012. Balance between regulatory T and Th17 cells in systemic lupus erythematosus: The old and the new. Clinical & Developmental Immunology 2012: 823085.
5. Xing, Q., B. Wang, H. Su, J. Cui, and J. Li. 2012. Elevated Th17 cells are accompanied by FoxP3+ Treg cells decrease in patients with lupus nephritis. Rheumatology International 32: 949–958.
6. Lin, J.H., J.P. Dutz, R.D. Sontheimer, and V.P. Werth. 2007. Pathophysiology of cutaneous lupus erythematosus. Clinical Reviews in Allergy and Immunology 33: 85–106.
7. Salem, S.A., H.M. Farouk, A.A. Mostafa, I.M. Hassan, W.M. Osman, H.A. Al-Shamy, et al. 2010. Keratinocyte and lymphocyte apoptosis: Relation to disease outcome in systemic lupus erythematosus patients with and without cutaneous manifestations. European Journal of Dermatology 20: 35–41.
8. Hahn, B.H., M.A. McMahon, A. Wilkinson, W.D. Wallace, D.I. Daikh, J.D. Fitzgerald, et al. 2012. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care & Research (Hoboken) 64: 797–808.
9. Nowling, T.K., and G.S. Gilkeson. 2011. Mechanisms of tissue injury in lupus nephritis. Arthritis Research & Therapy 13: 250.
10. Sanna, G., M.L. Bertolaccini, and M.A. Khamashta. 2008. Neuropsychiatric involvement in systemic lupus erythematosus: Current therapeutic approach. Current Pharmaceutical Design 14: 1261–1269.
11. Trysberg, E., K. Nylen, L.E. Rosengren, and A. Tarkowski. 2003. Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis and Rheumatism 48: 2881–2887.
12. Brzoska, T., T.A. Luger, C. Maaser, C. Abels, and M. Bohm. 2008. Alpha-melanocyte-stimulating hormone and related tripeptides: Biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocrine Reviews 29: 581–602.
13. Catania, A. 2010. Melanocortins: Multiple actions and therapeutic potential. New York, Austin, Tex.: Springer Science+Business Media; Landes Bioscience, 153.
14. Si, J., Y. Ge, S. Zhuang, L. Juan Wang, S. Chen, and R. Gong. 2013. Adrenocorticotropic hormone ameliorates acute kidney injury by steroidogenic-dependent and -independent mechanisms. Kidney International 83: 635–646.
15. Catania, A. 2007. The melanocortin system in leukocyte biology. Journal of Leukocyte Biology 81: 383–392.
16. Bohm, M., J. Ehrchen, and T.A. Luger. 2012. Beneficial effects of the melanocortin analogue Nle(4)-d-Phe(7)-alpha-MSH in acne vulgaris. Journal of the European Academy of Dermatology and Venereology 28: 108–111.
17. Konig, S., T.A. Luger, and T.E. Scholzen. 2006. Monitoring neuropeptide-specific proteases: Processing of the proopiomelanocortin peptides adrenocorticotropin and alpha-melanocyte-stimulating hormone in the skin. Experimental Dermatology 15: 751–761.
18. Schioth, H.B., R. Muceniece, M. Larsson, F. Mutulis, M. Szardenings, P. Prusis, et al. 1997. Binding of cyclic and linear MSH core peptides to the melanocortin receptor subtypes. European Journal of Pharmacology 319: 369–373.
19. Mountjoy, K.G., L.S. Robbins, M.T. Mortrud, and R.D. Cone. 1992. The cloning of a family of genes that encode the melanocortin receptors. Science 257: 1248–1251.
20. Abdel-Malek, Z., M.C. Scott, I. Suzuki, A. Tada, S. Im, L. Lamoreux, et al. 1992. The melanocortin-1 receptor is a key regulator of human cutaneous pigmentation. Pigment Cell Research 13(Suppl 8): 156–162.
21. Chan, L.F., L.A. Metherell, and A.J. Clark. 2011. Effects of melanocortins on adrenal gland physiology. European Journal of Pharmacology 660: 171–180.
22. Magenis, R.E., L. Smith, J.H. Nadeau, K.R. Johnson, K.G. Mountjoy, and R.D. Cone. 1994. Mapping of the ACTH, MSH, and neural (MC3 and MC4) melanocortin receptors in the mouse and human. Mammalian Genome 5: 503–508.
23. Mountjoy, K.G., M.T. Mortrud, M.J. Low, R.B. Simerly, and R.D. Cone. 1994. Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain. Molecular Endocrinology 8: 1298–1308.
24. Lasaga, M., L. Debeljuk, D. Durand, T.N. Scimonelli, and C. Caruso. 2008. Role of alpha-melanocyte stimulating hormone and melanocortin 4 receptor in brain inflammation. Peptides 29: 1825–1835.
25. Catania, A., S. Gatti, G. Colombo, and J.M. Lipton. 2004. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacological Reviews 56: 1–29.
26. Sarkar, S., G. Legradi, and R.M. Lechan. 2002. Intracerebroventricular administration of alpha-melanocyte stimulating hormone increases phosphorylation of CREB in TRH- and CRH-producing neurons of the hypothalamic paraventricular nucleus. Brain Research 945: 50–59.
27. Busca, R., and R. Ballotti. 2000. Cyclic AMP a key messenger in the regulation of skin pigmentation. Pigment Cell Research 13: 60–69.
28. Manna, S.K., and B.B. Aggarwal. 1998. Alpha-melanocyte-stimulating hormone inhibits the nuclear transcription factor NF-kappa B activation induced by various inflammatory agents. Journal of Immunology 161: 2873–2880.
29. Mandrika, I., R. Muceniece, and J.E. Wikberg. 2001. Effects of melanocortin peptides on lipopolysaccharide/interferon-gamma-induced NF-kappaB DNA binding and nitric oxide production in macrophage-like RAW 264.7 cells: Evidence for dual mechanisms of action. Biochemical Pharmacology 61: 613–621.
30. Chai, B., J.Y. Li, W. Zhang, J.B. Ammori, and M.W. Mulholland. 2007. Melanocortin-3 receptor activates MAP kinase via PI3 kinase. Regulatory Peptides 139: 115–121.
31. Buggy, J.J. 1998. Binding of alpha-melanocyte-stimulating hormone to its G-protein-coupled receptor on B-lymphocytes activates the Jak/STAT pathway. Biochemical Journal 331(Pt 1): 211–216.
32. Hofland, J., P.J. Delhanty, J. Steenbergen, L.J. Hofland, P.M. van Koetsveld, F.H. van Nederveen, et al. 2012. Melanocortin 2 receptor-associated protein (MRAP) and MRAP2 in human adrenocortical tissues: Regulation of expression and association with ACTH responsiveness. Journal of Clinical Endocrinology and Metabolism 97: E747–E754.
33. Carey, R.A., A.M. Harvey, and J.E. Howard. 1950. The effect of adrenocorticotropic hormone (ACTH) and cortisone on the course of disseminated lupus erythematosus and peri-arteritis nodosa. Bulletin of the Johns Hopkins Hospital 87: 425–460.
34. Soffer, L.J., and R. Bader. 1952. Corticotropin and cortisone in acute disseminated lupus erythematosus; results of long-term use. Journal of the American Medical Association 149: 1002–1008.
35. Lipton, J.M., G. Ceriani, A. Macaluso, D. McCoy, K. Carnes, J. Biltz, et al. 1994. Antiinflammatory effects of the neuropeptide alpha-MSH in acute, chronic, and systemic inflammation. Annals of the New York Academy of Sciences 741: 137–148.
36. Lipton, J.M., and A. Catania. 1997. Anti-inflammatory actions of the neuroimmunomodulator alpha-MSH. Immunology Today 18: 140–145.
37. Kaneva, M.K., M.J. Kerrigan, P. Grieco, G.P. Curley, I.C. Locke, and S.J. Getting. 2012. Chondroprotective and anti-inflammatory role of melanocortin peptides in TNF-alpha activated human C-20/A4 chondrocytes. British Journal of Pharmacology 167: 67–79.
38. Capsoni, F., A.M. Ongari, E. Reali, and A. Catania. 2009. Melanocortin peptides inhibit urate crystal-induced activation of phagocytic cells. Arthritis Research & Therapy 11: R151.
39. Delgado, R., A. Carlin, L. Airaghi, M.T. Demitri, L. Meda, D. Galimberti, et al. 1998. Melanocortin peptides inhibit production of proinflammatory cytokines and nitric oxide by activated microglia. Journal of Leukocyte Biology 63: 740–745.
40. Grabbe, S., R.S. Bhardwaj, K. Mahnke, M.M. Simon, T. Schwarz, and T.A. Luger. 1996. alpha-Melanocyte-stimulating hormone induces hapten-specific tolerance in mice. Journal of Immunology 156: 473–478.
41. Adachi, S., T. Nakano, H. Vliagoftis, and D.D. Metcalfe. 1999. Receptor-mediated modulation of murine mast cell function by alpha-melanocyte stimulating hormone. Journal of Immunology 163: 3363–3368.
42. Taylor, A.W., J.W. Streilein, and S.W. Cousins. 1994. Alpha-melanocyte-stimulating hormone suppresses antigen-stimulated T cell production of gamma-interferon. Neuroimmunomodulation 1: 188–194.
43. Manna, S.K., A. Sarkar, and Y. Sreenivasan. 2006. Alpha-melanocyte-stimulating hormone down-regulates CXC receptors through activation of neutrophil elastase. European Journal of Immunology 36: 754–769.
44. Auriemma, M., T. Brzoska, L. Klenner, V. Kupas, T. Goerge, M. Voskort, et al. 2012. alpha-MSH-stimulated tolerogenic dendritic cells induce functional regulatory T cells and ameliorate ongoing skin inflammation. Journal of Investigative Dermatology 132: 1814–1824.
45. Becher, E., K. Mahnke, T. Brzoska, D.H. Kalden, S. Grabbe, and T.A. Luger. 1999. Human peripheral blood-derived dendritic cells express functional melanocortin receptor MC-1R. Annals of the New York Academy of Sciences 885: 188–195.
46. Bhardwaj, R., E. Becher, K. Mahnke, M. Hartmeyer, T. Schwarz, T. Scholzen, et al. 1997. Evidence for the differential expression of the functional alpha-melanocyte-stimulating hormone receptor MC-1 on human monocytes. Journal of Immunology 158: 3378–3384.
47. Rennalls, L.P., T. Seidl, J.M. Larkin, C. Wellbrock, M.E. Gore, T. Eisen, et al. 2010. The melanocortin receptor agonist NDP-MSH impairs the allostimulatory function of dendritic cells. Immunology 129: 610–619.
48. Scholzen, T.E., C. Sunderkotter, D.H. Kalden, T. Brzoska, M. Fastrich, T. Fisbeck, et al. 2003. Alpha-melanocyte stimulating hormone prevents lipopolysaccharide-induced vasculitis by down-regulating endothelial cell adhesion molecule expression. Endocrinology 144: 360–370.
49. Brzoska, T., D. Kalden, M. Fastrich, M. Moller, H. Schioth, J. Wikkberg, et al. 1999. Two new a-melanocyte stimulating hormone (a-MSH) analogues (MS05 and MS09) are potent immunomodulators in vivo and in vitro. J Investigational Dermatology 113: 482.
50. Rinne, P., W. Nordlund, I. Heinonen, A.M. Penttinen, A. Saraste, S.T. Ruohonen, et al. 2013. alpha-Melanocyte-stimulating hormone regulates vascular NO availability and protects against endothelial dysfunction. Cardiovascular Research 97: 360–368.
51. Rajora, N., G. Boccoli, A. Catania, and J.M. Lipton. 1997. alpha-MSH modulates experimental inflammatory bowel disease. Peptides 18: 381–385.
52. Galimberti, D., P. Baron, L. Meda, E. Prat, E. Scarpini, R. Delgado, et al. 1999. Alpha-MSH peptides inhibit production of nitric oxide and tumor necrosis factor-alpha by microglial cells activated with beta-amyloid and interferon gamma. Biochemical and Biophysical Research Communications 263: 251–256.
53. Caruso, C., D. Durand, H.B. Schioth, R. Rey, A. Seilicovich, and M. Lasaga. 2007. Activation of melanocortin 4 receptors reduces the inflammatory response and prevents apoptosis induced by lipopolysaccharide and interferon-gamma in astrocytes. Endocrinology 148: 4918–4926.
54. Nicolaou, A., S.E. Estdale, M. Tsatmali, D.P. Herrero, and A.J. Thody. 2004. Prostaglandin production by melanocytic cells and the effect of alpha-melanocyte stimulating hormone. FEBS Letters 570: 223–226.
55. Yoon, S.W., J.S. Chun, M.H. Sung, J.Y. Kim, and H. Poo. 2008. alpha-MSH inhibits TNF-alpha-induced matrix metalloproteinase-13 expression by modulating p38 kinase and nuclear factor kappaB signaling in human chondrosarcoma HTB-94 cells. Osteoarthritis and Cartilage 16: 115–124.
56. Leoni, G., H.B. Patel, A.L. Sampaio, F.N. Gavins, J.F. Murray, P. Grieco, et al. 2008. Inflamed phenotype of the mesenteric microcirculation of melanocortin type 3 receptor-null mice after ischemia-reperfusion. FASEB Journal 22: 4228–4238.
57. Taylor, A.W. 2005. The immunomodulating neuropeptide alpha-melanocyte-stimulating hormone (alpha-MSH) suppresses LPS-stimulated TLR4 with IRAK-M in macrophages. Journal of Neuroimmunology 162: 43–50.
58. Sarkar, A., Y. Sreenivasan, and S.K. Manna. 2003. alpha-Melanocyte-stimulating hormone inhibits lipopolysaccharide-induced biological responses by downregulating CD14 from macrophages. FEBS Letters 553: 286–294.
59. Bhardwaj, R.S., A. Schwarz, E. Becher, K. Mahnke, Y. Aragane, T. Schwarz, et al. 1996. Pro-opiomelanocortin-derived peptides induce IL-10 production in human monocytes. Journal of Immunology 156: 2517–2521.
60. Taylor, A., and K. Namba. 2001. In vitro induction of CD25+ CD4+ regulatory T cells by the neuropeptide alpha-melanocyte stimulating hormone (alpha-MSH). Immunology and Cell Biology 79: 358–367.
61. Kokot, A., A. Sindrilaru, M. Schiller, C. Sunderkotter, C. Kerkhoff, B. Eckes, et al. 2009. alpha-melanocyte-stimulating hormone suppresses bleomycin-induced collagen synthesis and reduces tissue fibrosis in a mouse model of scleroderma: Melanocortin peptides as a novel treatment strategy for scleroderma? Arthritis and Rheumatism 60: 592–603.
62. Bitto, A., F. Polito, N. Irrera, M. Calo, L. Spaccapelo, H.R. Marini, et al. 2012. Protective effects of melanocortins on short-term changes in a rat model of traumatic brain injury*. Critical Care Medicine 40: 945–951.
63. Ottani, A., M. Galantucci, E. Ardimento, L. Neri, F. Canalini, A. Calevro, et al. 2013. Modulation of the JAK/ERK/STAT signaling in melanocortin-induced inhibition of local and systemic responses to myocardial ischemia/reperfusion. Pharmacological Research 72: 1–8.
64. Henri, P., S. Beaumel, A. Guezennec, C. Poumes, P.E. Stoebner, M.J. Stasia, et al. 2012. MC1R expression in HaCaT keratinocytes inhibits UVA-induced ROS production via NADPH oxidase- and cAMP-dependent mechanisms. Journal of Cellular Physiology 227: 2578–2585.
65. Muffley, L.A., K.Q. Zhu, L.H. Engrav, N.S. Gibran, and A.M. Hocking. 2011. Spatial and temporal localization of the melanocortin 1 receptor and its ligand alpha-melanocyte-stimulating hormone during cutaneous wound repair. Journal of Histochemistry and Cytochemistry 59: 278–288.
66. Slominski, A., and J. Wortsman. 2000. Neuroendocrinology of the skin. Endocrine Reviews 21: 457–487.
67. Bohm, M., M. Raghunath, C. Sunderkotter, M. Schiller, S. Stander, T. Brzoska, et al. 2004. Collagen metabolism is a novel target of the neuropeptide alpha-melanocyte-stimulating hormone. Journal of Biological Chemistry 279: 6959–6966.
68. Lindskog, A., K. Ebefors, M.E. Johansson, B. Stefansson, A. Granqvist, M. Arnadottir, et al. 2010. Melanocortin 1 receptor agonists reduce proteinuria. Journal of the American Society of Nephrology 21: 1290–1298.
69. Benjamins, J.A., L. Nedelkoska, B. Bealmear, and R.P. Lisak. 2013. ACTH protects mature oligodendroglia from excitotoxic and inflammation-related damage in vitro. Glia 61: 1206–1217.
70. Caruso, C.M., L. Carniglia, D. Durand, T.N. Scimonelli, and M. Lasaga. 2013. Astrocytes: New targets of melanocortin 4 receptor actions. Journal of Molecular Endocrinology 51: R33–R50.
71. Caruso, C., C. Mohn, A.L. Karara, V. Rettori, H. Watanobe, H.B. Schioth, et al. 2004. Alpha-melanocyte-stimulating hormone through melanocortin-4 receptor inhibits nitric oxide synthase and cyclooxygenase expression in the hypothalamus of male rats. Neuroendocrinology 79: 278–286.
72. Berg, A.L., and P. Nilsson-Ehle. 1996. ACTH lowers serum lipids in steroid-treated hyperlipemic patients with kidney disease. Kidney International 50: 538–542.
73. Berg, A.L., P. Nilsson-Ehle, and M. Arnadottir. 1999. Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy. Kidney International 56: 1534–1543.
74. Berg, A.L., P. Hansson, and P. Nilsson-Ehle. 1991. ACTH 1–24 decreases hepatic lipase activities and low density lipoprotein concentrations in healthy men. Journal of Internal Medicine 229: 201–203.
75. Berg, A.L., and P. Nilsson-Ehle. 1994. Direct effects of corticotropin on plasma lipoprotein metabolism in man—studies in vivo and in vitro. Metabolism 43: 90–97.
76. Montero-Melendez, T., H.B. Patel, M. Seed, S. Nielsen, T.E. Jonassen, and M. Perretti. 2011. The melanocortin agonist AP214 exerts anti-inflammatory and proresolving properties. American Journal of Pathology 179: 259–269.
77. Oates, J.C. 2010. The biology of reactive intermediates in systemic lupus erythematosus. Autoimmunity 43: 56–63.
78. Decker, D., C. Grant, L. Oh, P. Becker, D. Young, and S. Jordan. 2014. Immunomodulatory effects of H.P. Acthar Gel on B cell development in the NZB/W F1 mouse model of systemic lupus erythematosus. Lupus 23: 802–812.
79. Pranzatelli, M.R., E.D. Tate, N.R. McGee, A.L. Travelstead, J.A. Colliver, J.M. Ness, et al. 2013. BAFF/APRIL system in pediatric OMS: Relation to severity, neuroinflammation, and immunotherapy. Journal of Neuroinflammation 10: 10.
80. Taylor, A.W., and D.J. Lee. 2011. The alpha-melanocyte stimulating hormone induces conversion of effector T cells into Treg cells. Journal of Transplantation 2011: 246856.
81. McMahon, M., B.H. Hahn, and B.J. Skaggs. 2011. Systemic lupus erythematosus and cardiovascular disease: Prediction and potential for therapeutic intervention. Expert Review of Clinical Immunology 7: 227–241.
82. He, X., P. Xue, X. Xu, G. Luo, G. Zhou, P. Nilsson-Ehle, et al. 2006. Short-term administration of ACTH improves plasma lipid profile and renal function in kidney transplant patients. Transplantation Proceedings 38: 1371–1374.
83. Berg, A.L., A.T. Rafnsson, M. Johannsson, J. Dallongeville, and M. Arnadottir. 2006. The effects of adrenocorticotrophic hormone and an equivalent dose of cortisol on the serum concentrations of lipids, lipoproteins, and apolipoproteins. Metabolism 55: 1083–1087.
84. Bhardwaj, R.S., and T.A. Luger. 1994. Proopiomelanocortin production by epidermal cells: Evidence for an immune neuroendocrine network in the epidermis. Archives for Dermatological Research Archiv für Dermatologische Forschung 287: 85–90.
85. Luger, T.A., R.S. Bhardwaj, S. Grabbe, and T. Schwarz. 1996. Regulation of the immune response by epidermal cytokines and neurohormones. Journal of Dermatological Science 13: 5–10.
86. Kadekaro, A.L., R. Kavanagh, H. Kanto, S. Terzieva, J. Hauser, N. Kobayashi, et al. 2005. alpha-Melanocortin and endothelin-1 activate antiapoptotic pathways and reduce DNA damage in human melanocytes. Cancer Research 65: 4292–4299.
87. Bohm, M., U. Schulte, H. Kalden, and T.A. Luger. 1999. Alpha-melanocyte-stimulating hormone modulates activation of NF-kappa B and AP-1 and secretion of interleukin-8 in human dermal fibroblasts. Annals of the New York Academy of Sciences 885: 277–286.
88. Chen, W., J. Li, H. Qu, Z. Song, Z. Yang, J. Huo, et al. 2013. The melanocortin 1 receptor (MC1R) inhibits the inflammatory response in Raw 264.7 cells and atopic dermatitis (AD) mouse model. Molecular Biology Reports 40: 1987–1996.
89. Etori, M., K. Yonekubo, E. Sato, K. Mizukami, K. Hirahara, H. Karasuyama, et al. 2012. Melanocortin receptors 1 and 5 might mediate inhibitory effects of alpha-melanocyte-stimulating hormone on antigen-induced chronic allergic skin inflammation in IgE transgenic mice. Journal of Investigative Dermatology 132: 1925–1927.
90. Weening, J.J., V.D. D’Agati, M.M. Schwartz, S.V. Seshan, C.E. Alpers, G.B. Appel, et al. 2004. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Journal of the American Society of Nephrology 15: 241–250.
91. Moustafa, F.E., N.A. Soliman, A.M. Bakr, and I.M. El Shwaf. 2014. Assessment of detached podocytes in the Bowman’s space as a marker of disease activity in lupus nephritis. Lupus 23: 146–150.
92. Berg, A.L., and M. Arnadottir. 2004. ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnoses. Nephrology, Dialysis, Transplantation 19: 1305–1307.
93. Ponticelli, C., P. Passerini, M. Salvadori, C. Manno, B.F. Viola, S. Pasquali, et al. 2006. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. American Journal of Kidney Diseases 47: 233–240.
94. Gong, R. 2012. The renaissance of corticotropin therapy in proteinuric nephropathies. Nature Reviews Nephrology 8: 122–128.
95. Botte, D.A., I.L. Noronha, D.M. Malheiros, T.V. Peixoto, and S.B. de Mello. 2014. Alpha-melanocyte stimulating hormone ameliorates disease activity in an induced murine lupus-like model. Clinical and Experimental Immunology 177: 381–390.
96. Gong, R. 2014. Leveraging melanocortin pathways to treat glomerular diseases. Advances in Chronic Kidney Disease 21: 134–151.
97. Arnason, B.G., R. Berkovich, A. Catania, R.P. Lisak, and M. Zaidi. 2013. Mechanisms of action of adrenocorticotropic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis. Multiple Sclerosis 19: 130–136.
98. Huang, Q.H., M.L. Entwistle, J.D. Alvaro, R.S. Duman, V.J. Hruby, and J.B. Tatro. 1997. Antipyretic role of endogenous melanocortins mediated by central melanocortin receptors during endotoxin-induced fever. Journal of Neuroscience 17: 3343–3351.
99. Sinha, P.S., H.B. Schioth, and J.B. Tatro. 2003. Activation of central melanocortin-4 receptor suppresses lipopolysaccharide-induced fever in rats. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 284: R1595–R1603.
100. Tatro, J.B., and P.S. Sinha. 2003. The central melanocortin system and fever. Annals of the New York Academy of Sciences 994: 246–257.
101. Catania, A., and J.M. Lipton. 1993. alpha-Melanocyte stimulating hormone in the modulation of host reactions. Endocrine Reviews 14: 564–576.
102. Lipton, J.M., J.R. Glyn, and J.A. Zimmer. 1981. ACTH and alpha-melanotropin in central temperature control. Federation Proceedings 40: 2760–2764.
103. Ahmed, T.J., T. Montero-Melendez, M. Perretti, and C. Pitzalis. 2013. Curbing inflammation through endogenous pathways: Focus on melanocortin peptides. International Journal of Inflammation 2013: 985815.